Formestane

Formestane Overview

Formestane (chemically designated as 4-hydroxyandrostenedione) is a selective, Type I steroidal aromatase inhibitor. Chemically, it belongs to the class of organic compounds known as androgens and derivatives under the steroid and steroid derivatives subclass. Structurally, it is a 3-hydroxylated C19 steroid hormone featuring a 4-hydroxy substitution on an androst-4-ene-3,17-dione skeleton.

In clinical endocrinology and oncology, Formestane was historically developed as a second-generation irreversible aromatase inhibitor indicated for the treatment of advanced estrogen-receptor (ER) positive breast cancer in postmenopausal women. It was marketed in Europe under the trade name Lentaron as an intramuscular depot injection. Formestane functions by suppressing peripheral estrogen biosynthesis. Additionally, Formestane serves as a precursor/prohormone to 4-hydroxytestosterone, displaying weak androgenic activity. Due to its poor oral bioavailability requiring fortnightly (bi-weekly) deep intramuscular injections, its relatively low recommended dosage (250 mg), and the advent of potent, third-generation oral aromatase inhibitors (such as anastrozole, letrozole, and exemestane), Formestane was gradually phased out. The European marketing authorizations for Lentaron were voluntarily withdrawn, and Formestane was never approved by the US FDA. Furthermore, Formestane is strictly prohibited in and out of competition by the World Anti-Doping Agency (WADA) due to its illicit use as an anti-estrogenic and performance-enhancing agent among athletes.

What Is Formestane and How Does It Work?

Formestane is a small molecule steroidal analog that acts as a mechanism-based, suicide-inhibitor of the human aromatase enzyme (CYP19A1).

Its primary physiological and molecular mechanisms include:

• Irreversible Type I Aromatase Inhibition: Formestane competes directly with natural androgen substrates (androstenedione and testosterone) for binding at the active site of the aromatase cytochrome P450 enzyme complex. Once bound, aromatase processes Formestane into a reactive intermediate that forms a covalent bond with the active site, permanently inactivating the enzyme (suicide inactivation).
• Peripheral Estrogen Suppression: In postmenopausal women, primary estrogen synthesis shifts from the ovaries to peripheral tissues (such as adipose tissue, muscle, and breast tissue), driven by local aromatase conversion. By blocking peripheral aromatase, Formestane causes a rapid, sustained reduction in systemic and intratumoral estradiol levels.
• Deprivation of Trophic Signals: Estrogen-receptor positive breast cancer cells rely on circulating estradiol for growth and cell viability. Depriving these neoplastic cells of estrogen halts hormone-driven proliferation and induces tumor regression.
• Prohormone & Androgenic Activity: Formestane acts as a prohormone to 4-hydroxytestosterone, exerting mild androgenic effects that contribute to its biological profile.

Is Formestane FDA Approved?

No, Formestane was never approved by the US FDA for clinical prescription or commercial distribution in the United States. First approved for medical use internationally in Europe in 1993 under the trade name Lentaron (manufactured by Ciba-Geigy/Novartis), it served as a second-generation steroidal aromatase inhibitor for advanced postmenopausal breast cancer. However, following the development and clinical superiority of third-generation oral aromatase inhibitors (such as anastrozole, letrozole, and exemestane), its European marketing authorizations were voluntarily withdrawn in 2004.

What Was Formestane Used For?

• Historical endocrine treatment for estrogen-receptor positive advanced breast cancer in postmenopausal women.
• Historical second-line therapy for postmenopausal breast cancer progression following aminoglutethimide or tamoxifen treatment.
• Off-label / illicit misuse as an anti-estrogenic agent to prevent gynecomastia and fluid retention caused by anabolic steroid abuse in athletics.

Before Taking Formestane: Contraindications & Precautions

Strictly contraindicated in premenopausal women with intact, functional ovarian estrogen production. Do not use if you have a documented hypersensitivity to Formestane, steroid derivatives, or formulation excipients. Formestane was voluntarily withdrawn in Europe in 2004 due to the clinical superiority of third-generation oral aromatase inhibitors (e.g., anastrozole, letrozole) and was never approved by the US FDA. Use during pregnancy or lactation is strictly prohibited, as estrogen suppression and androgenic conversion cause severe embryo-fetal harm, intrauterine growth restriction, and virilization of female fetuses. Prohibited in and out of competition by WADA due to performance-enhancing misuse.

Who Should Not Take Formestane?

• Premenopausal women with intact, functional ovarian estrogen production.
• Individuals with a documented hypersensitivity or severe allergic reaction to Formestane, steroid derivatives, or formulation excipients.
• Pregnant or breastfeeding women.
• Individuals with severe liver impairment or underlying muscle disorders precluding deep intramuscular injections.

Formestane, Pregnancy & Fertility

Formestane is strictly contraindicated during pregnancy and breastfeeding. Suppression of estrogen biosynthesis and androgenic conversion during gestation causes severe embryo-fetal harm, intrauterine growth retardation, and potential virilization of female fetuses. In premenopausal women, aromatase inhibition disrupts normal pituitary-ovarian feedback, inducing compensatory ovarian hyperstimulation.

Tell Your Doctor Before Taking Formestane

Inform your physician or oncologist if you have a history of osteoporosis, osteopenia, severe hepatic dysfunction, or bleeding disorders before evaluating endocrine therapies. Disclose any past history of deep vein thrombosis or severe joint pain.

Formestane Dosage & Administration

Formulated as a powder for reconstitution as a deep intramuscular depot injection (Lentaron). Formestane is a withdrawn medication with no active clinical indications globally, making standard therapeutic dosing guidelines obsolete. Historically, the recommended clinical dosage for postmenopausal ER-positive advanced breast cancer was 250 mg administered via deep intramuscular injection into alternating gluteal buttocks every 14 days (fortnightly). Intravenous administration is strictly prohibited. It is no longer manufactured or available for legal medical administration.

Standard Formestane Dosing

• Historical Intramuscular Dosing (Lentaron): The standard recommended clinical dosage was 250 mg administered via deep intramuscular injection into the gluteal muscle every 14 days (fortnightly).
• Standardized modern dosing guidelines are obsolete because Formestane has been superseded by oral agents.

How Formestane Was Administered

• Formulated as a lyophilized powder requiring reconstitution with sterile saline (0.9% sodium chloride) immediately prior to injection.
• Administered strictly via deep intramuscular injection into alternating gluteal buttocks.
• Intravenous administration is strictly prohibited.

Formestane Clinical Efficacy & Research

Pivotal clinical trials conducted in postmenopausal women with advanced breast cancer demonstrated that Formestane 250 mg intramuscularly every two weeks produced objective tumor response rates of 20% to 30%, alongside significant pain relief from bone metastases. Biochemical studies confirmed that Formestane reduced plasma estradiol levels by approximately 60% to 70%. However, subsequent clinical evaluations indicated that the 250 mg fortnightly dose was sub-optimal compared to complete estrogen suppression achievable with newer third-generation oral agents (such as letrozole or anastrozole), which suppress plasma estrogen levels by over 98% without requiring painful injections.

Formestane Side Effects & Safety Profile

Common historical side effects included gluteal injection site pain, swelling, redness, sterile abscesses, hot flashes, facial flushing, sweating, arthralgias, myalgias, bone pain, fatigue, headache, and mild androgenic effects (alopecia, facial hair growth). Serious adverse risks included accelerated bone mineral density loss (osteopenia, osteoporosis, fragility fractures), deep muscle hematomas/nerve injury from injection, and adverse atherogenic lipid shifts (elevated LDL, decreased HDL). Holds no US FDA Black Box Warning due to its unapproved regulatory status in North America.

Common Formestane Side Effects

• Localized injection site pain, swelling, sterile abscesses, or redness at the gluteal injection site.
• Vasomotor symptoms, including hot flashes, sweating, and facial flushing.
• Arthralgias (joint pain), myalgias, and bone pain.
• Lethargy, mild fatigue, and headache.
• Alopecia or subtle facial hair growth due to mild androgenic activity.

Serious Formestane Adverse Events

• Accelerated Bone Mineral Density Loss: Chronic estrogen suppression accelerates bone turnover, increasing the risk of osteopenia, osteoporosis, and fragility fractures.
• Injection Site Complications: Deep gluteal muscle hematomas, nerve injury, or severe sterile abscesses.
• Cardiovascular & Lipid Alterations: Minor atherogenic shifts in lipid profiles (elevation of LDL cholesterol and reduction of HDL cholesterol).

Managing Formestane Side Effects

Hot flashes can be managed with behavioral modifications. Localized injection site soreness can be relieved with cold compresses. Patients undergoing prolonged aromatase inhibitor therapy require bone density monitoring and calcium/vitamin D supplementation.

Formestane Drug Interactions & What to Avoid

Co-administration with estrogen-containing therapies (e.g., HRT, topical estrogen creams) directly antagonizes the therapeutic aromatase-inhibiting action of Formestane. Strong CYP3A enzyme inducers may accelerate the hepatic metabolism of Formestane, reducing systemic drug exposure. Limit alcohol consumption to optimize bone mineral density retention and support hepatic health.

Formestane Drug-Drug Interactions

• Estrogen-Containing Therapies (e.g., HRT, Estrogen Creams): Co-administration with estrogens directly antagonizes the therapeutic aromatase-inhibiting effect of Formestane.
• Cytochrome P450 CYP3A Inducers: CYP3A enzyme inducers may accelerate the hepatic metabolism of Formestane, potentially reducing its systemic efficacy.

Formestane, Food & Alcohol

Systemic food interactions are minimal due to its intramuscular route of administration. Limit alcohol consumption to maintain liver health and optimize bone density retention.

Formestane: Missed Dose, Overdose & Storage

Dosing schedules are obsolete due to market withdrawal. Acute overdose via the intramuscular route is rare; accidental excessive administration produces profound estrogen suppression alongside exaggerated vasomotor and androgenic side effects, requiring supportive care. Legacy chemical reference samples should be stored in original light-resistant containers at room temperature (15°C–25°C), and reconstituted solutions must be injected immediately. Keep strictly out of reach of children.

Missed Dose of Formestane

Because Formestane was administered as a bi-weekly depot injection by healthcare professionals, missed appointments required immediate rescheduling to maintain therapeutic estrogen suppression.

Formestane Overdose & Emergency

Acute overdose via the intramuscular route is rare. Overdose would lead to profound estrogen suppression and exaggerated androgenic or vasomotor side effects. In cases of accidental toxicity, management consists of symptomatic and supportive care.

How to Store Formestane

Legacy or chemical reference samples should be kept in original light-resistant containers at controlled room temperature between 15°C and 25°C (59°F to 77°F). Reconstituted solutions should be injected immediately. Keep strictly out of reach of children.

Formestane Patient Management & Monitoring

Historical protocols required confirmation of postmenopausal status (serum estradiol, FSH), a baseline Dual-Energy X-ray Absorptiometry (DEXA) scan, liver function testing, and lipid panels prior to starting therapy. Periodically monitor bone mineral density during chronic estrogen deprivation therapy. Routinely inspect gluteal injection sites for deep muscle abscesses, sterile nodules, or hematoma formation.

Tests Before Starting Formestane

• Confirmation of postmenopausal status (serum estradiol and FSH levels).
• Baseline Dual-Energy X-ray Absorptiometry (DEXA) scan to evaluate bone mineral density.
• Baseline liver function tests and lipid panels.

Monitoring During Formestane Treatment

Monitor bone mineral density periodically during prolonged estrogen deprivation therapy. Regularly inspect gluteal injection sites for deep abscesses or hematomas.

Formestane Do’s and Don’ts

• Do maintain adequate daily intake of calcium and vitamin D to support bone health.
• Do report severe joint pain, severe bone pain, or injection site swelling to your physician.
• Do not use Formestane during pregnancy or if you are premenopausal.
• Do not purchase or use illicit Formestane products for sports performance enhancement.

Frequently Asked Questions

References

• DrugBank Database – Formestane Clinical and Pharmacological Profile (DB08905)
• Classyfire Database – Androgens and Derivatives Chemical Taxonomy Profile

Legal Disclaimer

The detailed medical and chemical information provided on this specific web page is intended strictly for educational and informational purposes regarding complex pharmacological mechanisms. It absolutely does not constitute professional medical advice, medical diagnosis, or specific treatment recommendations. Always consult a licensed healthcare provider before making any personal decisions regarding complex cardiovascular conditions, medication adjustments, or dietary changes.